New hope for hard-to-treat bone cancer? experimental drug combo enters human testing
NCT ID NCT07144254
First seen Jan 10, 2026 · Last updated May 23, 2026 · Updated 19 times
Summary
This early-phase study tests a new drug called tegavivint combined with the chemotherapy gemcitabine in people whose osteosarcoma (a type of bone cancer) has returned or not responded to standard treatments. The main goal is to find the safest dose of tegavivint when given with gemcitabine. About 24 participants will receive the drugs intravenously, and researchers will monitor side effects and whether the cancer stays under control for at least 4 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY OSTEOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Arthur M. Blank Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.